IGHE and allergic disease: In 2016, Bravin and Luyt conducted a clinical trial with the development of a recipe containing HE to be used in BE OIT, aiming to evaluate its safety and efficacy in a home-based, gradual up-dosing regimen for 15 children with persistent IgE-mediated HEA (SPT to EW and EY > 3 mm) and an allergic reaction to BE in the previous 6 months or a positive open OFC result.